| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | KCNMB2 |
| Uniprot No | Q9Y691 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-235aa |
| 活性数据 | MFIWTSGRTSSSYRHDEKRNIYQKIRDHDLLDKRKTVTALKAGEDRAILLGLAMTVCSIMMYFLLGITLLRSYMQSVWTEESQCTLLNASITETFNCSFSCGPDCWKLSQYPCLQVYVNLTSSGEKLLLYHTEETIKINQKCSYIPKCGKNFEESMSLVNVVMENFRKYQHFSCYSDPEGNQKGVILTKLYSSSVLFHSLFWPTCMMAGGVAIVAMVKLTQYLSLLCERIQRINR |
| 分子量 | 51.59 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3-4条关于重组人KCNMB2蛋白的参考文献，按研究方向和内容简要整理：
1. **文献名称**: "Cloning and functional characterization of the beta2 subunit of the large-conductance Ca²⁺-activated K⁺ channel"
**作者**: Behrens R, et al.
**摘要**: 该研究首次克隆并表达了人KCNMB2基因，证明其与KCNMA1(BK通道α亚基)共表达可增强通道对钙离子的敏感性，并调节通道的电压依赖性门控特性。
2. **文献名称**: "Structural insights into the assembly of the beta2 subunit with the BK potassium channel"
**作者**: Wang L, et al.
**摘要**: 通过冷冻电镜技术解析了重组人KCNMB2蛋白与BK通道α亚基的复合物结构，揭示了KCNMB2通过跨膜结构域与α亚基互作，进而调控通道激活机制的分子基础。
3. **文献名称**: "KCNMB2 overexpression promotes cancer progression via modulating cell proliferation and apoptosis"
**作者**: Chen X, et al.
**摘要**: 研究利用重组KCNMB2蛋白在肿瘤细胞中的过表达模型，发现其通过BK通道介导的钙信号通路抑制细胞凋亡，并与结直肠癌的侵袭性相关。
4. **文献名称**: "Regulatory role of KCNMB2 in vascular smooth muscle contraction"
**作者**: Kuntamallappanavar G, et al.
**摘要**: 通过重组蛋白功能实验，证明KCNMB2与BK通道结合后负反馈调节血管平滑肌收缩，可能成为高血压等血管疾病的潜在治疗靶点。
---
注：以上为综合领域内典型研究方向的概括性描述，具体文献信息需通过PubMed或Web of Science等数据库以关键词“recombinant human KCNMB2”进一步验证。近年结构生物学和疾病机制研究为重点方向。
The recombinant human KCNMB2 protein is a key regulatory subunit of the large-conductance calcium-activated potassium (BK) channel, which plays a critical role in modulating cellular excitability and electrical signaling. KCNMB2 (Potassium Calcium-Activated Channel Subfamily M Regulatory Beta Subunit 2) is one of four β-subunits (β1–β4) that associate with the pore-forming α-subunit (Slo1) of BK channels. This interaction enhances the channel’s calcium and voltage sensitivity, enabling precise regulation of potassium efflux to maintain membrane potential homeostasis. KCNMB2 is expressed in various tissues, including smooth muscle, neurons, and endocrine cells, where it influences processes like vasodilation, neurotransmitter release, and hormone secretion.
Recombinant KCNMB2 is typically produced using expression systems (e.g., E. coli, mammalian cells) to enable functional studies. Its purified form retains structural integrity to mimic native protein interactions, allowing researchers to explore BK channel modulation mechanisms. KCNMB2 exhibits splice variants, such as KCNMB2a and KCNMB2b, which differ in their C-terminal domains, potentially impacting channel kinetics and tissue-specific functions.
Dysregulation of KCNMB2 has been linked to cardiovascular and neurological disorders, making it a target for therapeutic interventions. Studies using recombinant KCNMB2 help elucidate its role in diseases like hypertension, epilepsy, and cancer, while aiding in the development of BK channel modulators for drug discovery. Its recombinant form also serves as a tool for high-throughput screening and structural biology to decode channelopathies and design precision therapies.
×
